Patents by Inventor Daniel T. Monaghan

Daniel T. Monaghan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phenanthryl piperazinyl dicarboxylic acids as selective NMDA receptor modulating agents
    Patent number: 6916816
    Abstract: Disclosed are compounds of formula (I) wherein: L is (a) optionally substituted by replacement of one or more of the hydrogen atoms on the phenanthrene ring system by one or more groups other than hydrogen; A is CH2, SO2 or C?O; X is CO2H, PO3H2, PO2H2, PO2HR5, PO2HOR5, SO3H, SO2H, or tetrazole; and R1, R2, R3, R4 and R5 are independently selected from H, alkyl, alkenyl, alkynyl, aryl and aralkyl; or a pharmaceutically acceptable acid salt or base addition salt or an in vivo hydrolysable ester or amide thereof.
    Type: Grant
    Filed: December 18, 2000
    Date of Patent: July 12, 2005
    Assignees: The Board of Regents of the University of Nebraska, The University of Bristol
    Inventors: Daniel T. Monaghan, David E. Jane, Heong Wai Tse
  • N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis
    Patent number: 6469027
    Abstract: The present invention relates to the novel finding that homocysteine affects the initiation and/or progress of atherosclerosis via a receptor-mediated growth factor effect on vascular smooth muscle cells. This growth factor effect can be inhibited by N-methyl-D-aspartate antagonists via a unique receptor that is in the NMDA receptor family. Through the use of cloning and other procedures, this homocysteine receptor can be characterized in order to develop novel pharmacologic strategies that the address the receptor for the prevention and treatment of atherosclerosis.
    Type: Grant
    Filed: December 29, 1999
    Date of Patent: October 22, 2002
    Assignee: The Board of Regents of the University of Nebraska
    Inventors: Thomas H. Rosenquist, Daniel T. Monaghan, Preston F. Gadson, Vincent J. Andaloro
  • N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis
    Patent number: 6025369
    Abstract: The present invention relates to the novel finding that homocysteine affects the initiation and/or progress of atherosclerosis via a receptor-mediated growth factor effect on vascular smooth muscle cells. This growth factor effect can be inhibited by N-methyl-D-aspartate antagonists via a unique receptor that is in the NMDA receptor family. Through the use of cloning and other procedures, this homocysteine receptor can be characterized in order to develop novel pharmacologic strategies that the address the receptor for the prevention and treatment of atherosclerosis.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: February 15, 2000
    Assignee: The Board of Regents of the University Nebraska
    Inventors: Thomas H. Rosenquist, Daniel T. Monaghan, Preston F. Gadson, Vincent J. Andaloro